Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Lisa M. Bloudek, PharmD, MS
Senior Partner and CEO
Curta
Seattle, WA
Senior Partner and CEO, Curta, Seattle, WA
Authored Items
Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting
Lisa M. Bloudek, PharmD, MS
,
LoAn K. Ho, PharmD
,
Neha Kapur, PharmD
,
Lonnie D. Brent, PharmD
September 2022 Vol 15, No 3
in
Business
,
Original Research
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS
,
James T. Kenney, RPh, MBA
,
Marlo Blazer, PharmD, BCOP
,
Lisa M. Bloudek, PharmD, MS
,
John Brokars, MS
,
Dinara Makenbaeva, MD, MBA
November 2019 Vol 12, No 7
in
Business
,
Original Research
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
Lisa M. Bloudek, PharmD, MS
,
Gary Branning, MBA
,
Dinara Makenbaeva, MD, MBA
,
Michael Eaddy, PharmD, PhD
December 2015 Vol 8, No 9
in
Business
,
Original Research
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
James T. Kenney, RPh, MBA
,
Anuja Roy, PhD, MBA
,
Jonathan K. Kish, PhD, MPH
,
Lisa M. Bloudek, PharmD, MS
,
David S. Siegel, MD, PhD
,
Sundar Jagannath, MD
,
Denise Globe, PhD
,
Emil T. Kuriakose, MD
,
Kristen Migliaccio-Walle, BS
June 2015, Vol 8, No 4
in
Business
Last modified: September 28, 2022